×

Please see full Prescribing Information for ANJESO, including  Important Safety Information and Boxed Warning, at www.anjeso.com.

Acute Care Therapeutics for Surgical Settings

Baudax Bio is a pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

About Baudax Bio

About Baudax Bio

We are committed to bringing meaningful therapeutic options to patients, healthcare providers, and payers.  We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA approved non-opioid therapy for use in the acute care setting.

About Us
Our Innovative Portfolio & Pipeline

Our Innovative Portfolio & Pipeline

On February 20, 2020, the FDA approved ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.  Our product pipeline contains valuable therapeutic candidates for patients and healthcare providers in acute care settings.

ANJESO (meloxicam) injection

Product Portfolio

Latest News

Baudax Bio Announces Date of Reconvened Special Meeting

View Press Release

Baudax Bio Announces Date of Reconvened Special Meeting

View Press Release

Baudax Bio to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021

View Press Release

Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends Baudax Bio Shareholders Vote “For” the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders

View Press Release

Leading Independent Advisory Firm Institutional Shareholder Services, Inc. Recommends Baudax Bio Shareholders Vote “For” the Proposed Additional Authorized Shares at Upcoming Special Meeting of Shareholders

View Press Release

Baudax Bio Announces Special Meeting of Shareholders to Vote on Proposed Increase in Number of Authorized Shares of Common Stock

View Press Release

Baudax Bio to Participate in the JMP Securities Life Sciences Conference

View Press Release

Baudax Bio’s ANJESO® Achieves Formulary Listing at Over 100 Institutions in Less Than One Year on the Market

View Press Release

Baudax Bio Announces $11.9 Million Registered Direct Offering

View Press Release

Baudax Bio Announces the Cancellation of Adjourned Portion of Annual Shareholder Meeting

View Press Release

Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign up today